Selected ongoing clinical trials. .

Aspirin or Warfarin to Prevent Stroke: The Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Study

This randomized, double-blind study, currently in Phase III, will compare the effectiveness of aspirin and warfarin in stroke prevention. Men and women 40 years of age or older who have experienced a mild stroke or transient ischemic attack within the previous 90 days are eligible to participate. Other inclusion and exclusion criteria also apply. For more information, see web sites: <http://www.clinicaltrials.gov/ct/gui/show/NCT00004728?order=16> and <http://www.sph.emory.edu/WASID/index.html>. Accessed March 5, 2003.

Contact: Harriet Howlett Smith, RN, WASID Study Coordinator, Department of Neurology, Emory University School of Medicine, 1440 Clifton Road, Atlanta, GA 30322; telephone [phone], email: [e-mail]

Assisted Movement Neuro-Rehabilitation: Veterans Administration Multisite Clinical Trials

A multisite clinical trial at VA Rehabilitation Centers in Houston, Los Angeles, and Palo Alto, CA, continues an investigation of the use of robots in the rehabilitation of hemiplegic patients. Patients with spinal cord injury who are at least 18 years of age are eligible to enroll in the randomized, single-group assignment efficacy study, which is now in Phase II. For more information, see web site: http://www.clinicaltrials.gov/c/gui/show/NCT00038324?order=29. Accessed March 5, 2003.

Contact: Charles C. Burgar, MD, Principal Investigator; Medical Director, Rehabilitation R&D Center, VA Medical Center, Clinical Assistant Professor of Functional Restoration, Department of Veterans Affairs, Palo Alto Health Care System, 3801 Miranda Avenue, Mail Stop 153, Palo Alto, CA 94304-1200; telephone [phone], email: [e-mail]

Carotid Occlusion Surgery Study

Patients with a stenosis of one of the main arteries in the neck may benefit from extracranial-intracranial bypass surgery. This randomized, Phase III study seeks to determine if this surgical procedure reduces risk of subsequent ipsilateral stroke in high-risk patients. Participants must be 18 to 85 years of age, with a transient ischemic attack or stroke having occurred within the previous 120 days. Patients who are pregnant or have conditions such as cancer, renal failure, liver disease, and congestive heart failure are not eligible. Other specific criteria apply. For more information, see web site: http://www.clinicaltrials.gov/ct/gui/show/NCT00029146?order=25. Accessed March 5, 2003.

Contact: William J. Powers, MD, Principal Investigator; East Building Imaging Center, Washington University School of Medicine, Box 8225, 4525 Scott Avenue, St. Louis, MO 63110; telephone [phone], fax [phone], email: [e-mail]

Effects of Exercise on Patients with Hemiparetic Stroke

Treadmill workouts are the basis of this study designed to find out if regular aerobic exercise with a task-specific gait training modality reduces the risk for recurrent cardiovascular events in chronic hemiparetic stroke patients. Participants will engage in 6 months of progressive graded treadmill training to see if improvements occur in cardiovascular fitness, functional mobility, and risk of subsequent cardiovascular events. Measurements of oxygen consumption, energy expenditure, and body composition are among the data to be considered. Men and women 40 to 80 years of age who are chronic hemiparetic stroke patients may apply. For more information, see web site: http://www.clinicaltrials.gov/ct/gui/show/NCT00018421?order= 23. Accessed March 5, 2003.

Contact: Richard F. Macko, MD, Principal Investigator; Associate Professor of Neurology, Baltimore Veterans Affairs Medical Center, VA Maryland Health Care System, 10 N. Greene Street, Baltimore, MD 21201, telephone [phone], email: [e-mail]

Safety, Efficacy, and Tolerability of Repinotan in Patients with Acute Ischemic Stroke

This randomized, double-blind, placebo-controlled study is designed to evaluate the effects of Repinotan in patients with acute ischemic stroke. Patients will be randomized to Repinotan IIC1 or placebo in a 1:1 ratio to assess the efficacy, safety, tolerability and pharmacokinetic/pharmacodynamic effects of this drug for a total treatment period of 72 hours. Men and women who are more than 18 years of age and who meet the specified criteria relating to acute ischemic stroke are eligible. For more information, see web site: http://www.clinicaltrials.gov/ct/gui/show/NCT00044915?order=18. Accessed March 5, 2003.

Contacts: Pamela Cyrus, MD, Associate Director, CNS Medical Research, Bayer Corp., 400 Morgan Lane, West Haven, CT 06516, telephone [phone]; Advanced Neurology Specialists, 400 13th Avenue S., Great Falls, MT 59405, telephone [phone]; Forsyth Medical Center, 3333 Silas Creek Parkway, Winston-Salem, NC 27103, telephone [phone], web site: http://www.forsythmedicalcenter.org/; Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, telephone [phone], fax [phone], email: [e-mail]

* Prepared by Esther L. Smith and Staci Lewis Webb.